Latanoprostene bunod
Chemical compound
- US DailyMed: Latanoprostene bunod
- S01EE06 (WHO)
- 4-Nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
- 860005-21-6
- 11156438
- DB11660
- 9331546
- I6393O0922
- D10441
- DTXSID101027765
- Interactive image
- C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O
InChI
- InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1
- Key:LOVMMUBRQUFEAH-UIEAZXIASA-N
Latanoprostene bunod (trade name Vyzulta) is an ophthalmic drug approved in the United States in 2017 for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.[3][4] It targets the trabecular meshwork directly.[4]
References
- ^ "Search Page - Drug and Health Product Register". 23 October 2014.
- ^ "Vyzulta- latanoprostene bunod solution/ drops". DailyMed. 1 May 2019. Retrieved 7 June 2022.
- ^ "FDA Approves Vyzulta (latanoprostene bunod) Ophthalmic Solution for Open-Angle Glaucoma, Ocular Hypertension" (Press release). Valeant Pharmaceuticals International, Inc.
- ^ a b Hoy SM (May 2018). "Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension". Drugs. 78 (7): 773–780. doi:10.1007/s40265-018-0914-6. PMC 5976683. PMID 29761382.
- v
- t
- e
- Apraclonidine
- Brimonidine (+timolol)
- Clonidine
- Dipivefrine
- Epinephrine
| muscarinic | |
|---|---|
| muscarinic/nicotinic | |
| acetylcholinesterase inhibitors |
(sulfonamides)
- Bimatoprost (+timolol)
- Latanoprost (+netarsudil, +timolol)
- Latanoprostene bunod
- Tafluprost
- Travoprost (+timolol)
- Unoprostone
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
